There is one clinical trial.
Patients with coronavirus disease (COVID-19) and pneumonitis often have hypoxemic respiratory failure and a need of supplementary oxygen. Guidelines recommend controlled oxygen, for most patients with a recommended interval of SpO2 between 92 and 96 %. We aimed to determine if closed-loop control of oxygen was feasible in patients with COVID-19 and could maintain SpO2 in the specified interval.
Description: Time in SpO2 target of 92-96 %Measure: Time in SpO2 target Time: 1 week
Description: Time with SpO2 not more than 2 % outside targetMeasure: Time with SpO2 not more than 2 % outside target Time: 1 week
Description: Time with SpO2 more than 2 % outside targetMeasure: Time with SpO2 more than 2 % outside target Time: 1 week
Description: Time with SpO2 < 85 %Measure: Time with SpO2 < 85 % Time: 1 week
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports